- Home
- NBTB vs NVCR Comparison
NBTB vs NVCR Comparison
Compare NBTB & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTB
- NVCR
- Stock Information
- Founded
- NBTB 1856
- NVCR 2000
- Country
- NBTB United States
- NVCR Switzerland
- Employees
- NBTB N/A
- NVCR N/A
- Industry
- NBTB Major Banks
- NVCR Medical/Dental Instruments
- Sector
- NBTB Finance
- NVCR Health Care
- Exchange
- NBTB Nasdaq
- NVCR Nasdaq
- Market Cap
- NBTB 2.2B
- NVCR 1.9B
- IPO Year
- NBTB N/A
- NVCR 2015
- Fundamental
- Price
- NBTB $43.82
- NVCR $17.60
- Analyst Decision
- NBTB Buy
- NVCR Buy
- Analyst Count
- NBTB 4
- NVCR 7
- Target Price
- NBTB $51.00
- NVCR $32.43
- AVG Volume (30 Days)
- NBTB 235.2K
- NVCR 1.4M
- Earning Date
- NBTB 07-28-2025
- NVCR 07-24-2025
- Dividend Yield
- NBTB 3.10%
- NVCR N/A
- EPS Growth
- NBTB 17.05
- NVCR N/A
- EPS
- NBTB 3.03
- NVCR N/A
- Revenue
- NBTB $569,473,000.00
- NVCR $621,711,000.00
- Revenue This Year
- NBTB $26.51
- NVCR $5.56
- Revenue Next Year
- NBTB $12.04
- NVCR $9.19
- P/E Ratio
- NBTB $14.49
- NVCR N/A
- Revenue Growth
- NBTB 13.26
- NVCR 18.27
- 52 Week Low
- NBTB $37.31
- NVCR $14.17
- 52 Week High
- NBTB $52.44
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- NBTB 61.42
- NVCR 49.74
- Support Level
- NBTB $42.23
- NVCR $16.81
- Resistance Level
- NBTB $44.25
- NVCR $18.59
- Average True Range (ATR)
- NBTB 1.05
- NVCR 0.74
- MACD
- NBTB 0.30
- NVCR 0.08
- Stochastic Oscillator
- NBTB 90.71
- NVCR 56.18
About NBTB NBT Bancorp Inc.
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.